Serum Auto-Antibodies in Neurological Diseases
NCT00704626 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2026-05-18
Summary
Under normal conditions our immune system protects us against infections and tumors. The immune system does this by recognizing that the infecting organism or the tumor is foreign to the body and attacking it. One way the immune system attacks a foreign target is by making proteins called antibodies that bind to the target. Sometimes, for reasons we poorly understand, the immune system wrongly identifies part of our own body as being foreign and attacks it. This can result in disease such as some forms of diabetes and thyroid disease, as well as some neurological diseases. In this study, one tablespoon of blood will be removed from each subject and tested to see if the immune system is making antibodies against components of the nerves and muscles. We also hope to learn if these antibodies contribute to the development or worsening of illnesses of the nervous system. Only one blood draw is required, but subjects may be asked to give up to 8 additional blood samples to see if the level of antibodies changes over time. Any additional blood draws would be performed at regularly scheduled clinic visits. There would be at least 3 months between blood draws over a period of up to 3 years, if requested by the physician.
Depending on your diagnosis, the physician may also request the collection of mouth (buccal) cells. This takes about one minute and is painless. The cells are collected by swishing a swab around your mouth. This cheek swab would be done with each blood draw.
Please note that this study is conducted ONLY at UC Davis and that all participants must be seen in our clinic located in Sacramento, CA. Results of the testing performed in this study are not given to the participants. This study is not intended to treat or diagnose any condition.
Conditions
- Multiple Sclerosis
- Myasthenia Gravis
- Transverse Myelitis
Interventions
- OTHER
-
Blood Draw
A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
- OTHER
-
Cheek swab
A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
Sponsors & Collaborators
-
University of California, Davis
lead OTHER
Principal Investigators
-
David Richman, MD · University of California, Davis
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-01-31
- Primary Completion
- 2031-03-31
- Completion
- 2031-03-31
Countries
- United States
Study Locations
More Related Trials
-
Plasma Exchange for Autoimmune Autonomic Failure
NCT00359346 ·Status: COMPLETED
-
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
NCT07337785 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
NCT02697292 ·Status: TERMINATED ·Phase: PHASE3
-
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
NCT00050245 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
NCT04708626 ·Status: COMPLETED
-
The EXPLORE MG Registry for Myasthenia Gravis
NCT03792659 ·Status: RECRUITING
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
NCT01623076 ·Status: ACTIVE_NOT_RECRUITING
-
Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy
NCT00268788 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies
NCT00006072 ·Status: UNKNOWN ·Phase: PHASE2
-
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
NCT07021209 ·Status: RECRUITING ·Phase: PHASE1
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA
-
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
NCT00666263 ·Status: COMPLETED ·Phase: PHASE3
-
Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection
NCT05198661 ·Status: RECRUITING ·Phase: NA
-
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
NCT06002945 ·Status: ACTIVE_NOT_RECRUITING
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
NCT02110706 ·Status: COMPLETED ·Phase: PHASE2
-
Tissue Repository for Studies of Myasthenia Gravis
NCT02902536 ·Status: COMPLETED
-
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
NCT04175522 ·Status: COMPLETED ·Phase: PHASE2
-
Neuropathy and Anti-GFAP Antibodies
NCT05742087 ·Status: UNKNOWN
-
sCD163 as a Potential Biomarker in Guillain- Barré Syndrome
NCT02582853 ·Status: UNKNOWN
-
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
NCT03864185 ·Status: COMPLETED ·Phase: PHASE2
-
Application of Artificial Intelligence in Precision Medicine and Healthcare
NCT06879210 ·Status: RECRUITING ·Phase: NA
-
National, Multicentric Registry Study on Neuroimmunological Diseases in China
NCT06443333 ·Status: RECRUITING
-
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
NCT04561557 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Anti-MAG First Administration to Human
NCT00622609 ·Status: COMPLETED ·Phase: PHASE1